K-ras exon 4A has a tumour suppressor effect on carcinogen-induced murine colonic adenoma formation

Journal of Pathology

Volumn 220, Issue 5, 2010, Pages 542-550

  Luo, Feijun ^a,b   Ye, Hongtao ^a,c   Hamoudi, Rifat ^a   Dong, Gehong ^a   Zhang, Wenyan ^a   Patek, Charles E ^d   Poulogiannis, George ^a   Arends, Mark J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

1,2 dimethylhydrazine; Adenoma; Carcinogen; Colon; Exon 4a; K ras; Mouse

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CARCINOGEN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; COLON ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; EXON; FEMALE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HETEROZYGOTE; HOMOZYGOSITY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; SURVIVAL; WILD TYPE;

1,2-DIMETHYLHYDRAZINE; ADENOMA; ANIMALS; APOPTOSIS; CARCINOGENS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; ENZYME ACTIVATION; EXONS; GENES, RAS; GENES, TUMOR SUPPRESSOR; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 77949779384     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2672     Document Type: Article

References (34)

1. Arends MJ, McGregor AH, Toft NJ, Brown EJ, Wyllie AH. Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability. Br J Cancer 1993;68:1127-1133.
2. Arends MJ, McGregor AH, Wyllie AH. Apoptosis is inversely related to necrosis and determines net growth in tumours bearing constitutively expressed myc, ras, and HPV oncogenes. Am J Pathol 1994;144:1045-1057.
3. Brooks DG, James RM, Patek CE, Williamson J, Arends MJ. Mutant K-ras enhances apoptosis in embryonic stem cells in combination with DNA damage and is associated with increased levels of p19 ARF. Oncogene 2001;20:2144-2152.
4. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene 2003;22:8999-9006.
5. James RM, Arends MJ, Plowman S, Brooks DG, Miles CG, West JD, et al. K-ras proto-oncogene exhibits tumour suppressor activity as its absence promotes tumourigenesis in murine teratomas. Mol Cancer Res 2003;1:820-825.
6. Fodde RJ, Kuipers C, Rosenberg, R, Smits M, Kielman C, Gaspar JH, et al. Tumour induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003;4:111-120.
7. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004;5:375-387.
8. Luo F, Brooks DG, Ye H, Hamoudi R, Poulogiannis G, Patek CE, et al. Conditional expression of mutated K-ras accelerates intestinal tumourigenesis in Msh2-deficient mice. Oncogene 2007;26:4415-4427.
9. Luo F, Hamoudi R, Brooks DG, Patek CE, Arends MJ. Stem cell gene expression changes induced specifically by mutated K-ras. Gene Expression 2007;14:101-115.
10. Zhang Z, Wang Y, Vikis HG, Johnson L, Li J, Anderson MW, et al. Wild-type Kras2 can inhibit lung carcinogenesis in mice. Nature Genet 2001;29:25-33.
11. Patek CE, Arends MJ, Wallace W, Luo F, Hagan S, Brownstein DG, et al. Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis. Exp Cell Res 2008;314:1105-1114.
12. Hancock JF. Ras proteins: different signals from different locations. Nature Rev Mol Cell Biol 2003;4:373-384.
13. Voice JK, Klemke RL, Le A, Jackson JH. Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J Biol Chem 1999;1999:17164-17170.
14. Liao J, Wolfman JC, Wolfman A. K-Ras regulates the steady-state expression of matrix metalloproteinase 2 in fibroblasts. J Biol Chem 2003;278:31871-31878.
15. Potenza N, Vecchione C, Notte A, De Rienzo A, Rosica A, Bauer L, et al. Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice. EMBO Rep 2005;6:432-437.
16. Plowman SJ, Williamson DJ, O'Sullivan MJ, Doig J, Ritchie AM, Harrison DJ, et al. While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable. Mol Cell Biol 2003;23:9245-9250.
17. Plowman SJ, Arends MJ, Brownstein DG, Luo F, Devenney PS, Rose L, et al. The K-Ras 4A isoform promotes apoptosis but does not affect either lifespan or spontaneous tumour incidence in ageing mice. Exp Cell Res 2006;312:16-26.
18. Patek CE, Arends MJ, Rose L, Luo F, Walker M, Devenney PS, et al. The pro-apoptotic K-Ras 4A proto-oncoprotein does not affect tumorigenesis in the Apc-Min/+ mouse small intestine. BMC Gastroenterol 2008;13:8-24.
19. Plowman SJ, Berry RL, Bader SA, Luo F, Arends MJ, Harrison DJ, et al. K-ras 4A and 4B are co-expressed widely in human tissues, and their ratio is altered in sporadic colorectal cancer. J Exp Clin Cancer Res 2006;25:259-267.
20. Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N et al. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol 2009;219:435-445.
21. Hall CN, Badawi AF, O'Connor PJ, Saffhill R. The detection of alkylation damage in the DNA of human gastrointestinal tissues. Br J Cancer 1991;64:59-63.
22. 6-alkylguanine DNA-alkyltransferase activity in normal colorectal tissue is associated with colorectal tumours containing a GC → AT transition in the K-ras oncogene. Carcinogenesis 1997;18:1299-1302.
23. 6-methylguanine-DNA methyltransferases. J. Biol. Chem 1994;269:730-733.
24. Hickman MJ, Samson LD. Apoptotic signaling in response to a single type of DNA lesion, O6-methylguanine. Mol Cell 2004;14:105-116.
25. Jacoby RF, Llor X, Teng B-B, Davidson NO, Brasitus TA. Mutations in the K-ras oncogene induced by 1,2-dimethylhydrazine in preneoplasic and neoplastic rat colonic mucosa. J Clin Invest 1991;87:624-630.
26. Deschner EE, Long FC. Colonic neoplasms in mice produced with six injections of 1,2-dimethylhydrazine. Oncology 1977;34:255-257.
27. Deschner EE, Long FC, Maskens AP. Relationship between dose, time and tumor yield in mouse dimethylhydrazine-induced colon tumorigenesis. Cancer Lett 1979;8:23-28.
28. Diwan BA, Meier H, Blackman KE. Genetic differences in the induction of colorectal tumors by 1,2-dimethylhydrazine in inbred mice. J Natl Cancer Inst 1977;59:455-458.
29. Min mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. Int J Exp Pathol 2009;90:558-574.
30. Maher J, Baker DA, Manning M, Dibb NJ, Roberts IAG. Evidence for cell-specific differences in transformation by N-, H- and K-ras. Oncogene 1995;11:1639-1647.
31. Mercatante D, Kole R. Modifications of alternative splicing pathways as a potential approach to chemotherapy. Pharmacol Ther 2000;85:237- 243.
32. Takahashi M, Fukuda K, Sugimura T, Wakabayashi K. β-catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumours. Cancer Res 1998;58:42-46.
33. Butz JA, Roberts KG, Edwards JS. Detecting changes in the relative expression of KRAS2 splice variants using polymerase colonies. Biotechol Prog 2004;20:1836-1839.
34. Sazani P, Kole R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest 2003;122:481- 486.